SCHEMBL6702065

SCHEMBL6702065

Nc1nc2ccccc2c2c1ncn2CCOCCCc1cccs1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 10/20 0.49
ADORA2A P29274 3/20 0.49
LMNA P02545 2/20 0.49
POLB P06746 1/20 0.49
HRH2 P25021 1/20 0.49
ADRA1D P25100 1/20 0.49
HTR2A P28223 1/20 0.49
ADRA1A P35348 1/20 0.49
NUDT1 P36639 1/20 0.49
HTR2B P41595 1/20 0.49
PDE4D Q08499 1/20 0.49
KCNH2 Q12809 1/20 0.49
TLR8 Q9NR97 6/20 0.40
ADORA3 P0DMS8 2/20 0.37
ADORA1 P30542 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
ADORA2B P29275 2/20 0.35
ALDH1A1 P00352 1/20 0.35
NCF1 P14598 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6107460 0.86 TLR7 (0.55) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL2059062 0.85 TLR7 (0.48) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL6699331 0.85 TLR7 (0.54) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL6694771 0.84 TLR7 (0.51) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL6730779 0.83 TLR7 (0.52) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL6695790 0.82 TLR7 (0.51) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL7180218 0.82 TLR7 (0.54) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL6700242 0.82 LMNA (0.41) LMNAPOLBSMN1; SMN2ALDH1A1
SCHEMBL6702071 0.81 TLR7 (0.50) TLR7ADORA2ALMNAPOLBHRH2
SCHEMBL4330880 0.81 TLR7 (0.59) TLR7ADORA2ALMNAPOLBHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-15 US claimed
US-6664260-B2 Viricides; anticarcinogneic agents; induction cytokine biosynthesis 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US claimed
EP-1339715-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-03 EP claimed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US claimed
WO-2002046193-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO claimed
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-15 US disclosed
US-6664260-B2 Viricides; anticarcinogneic agents; induction cytokine biosynthesis 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
EP-1339715-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-03 EP disclosed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
WO-2002046193-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 TLR7 35/4885ADORA2A 3459/4885LMNA 3958/4885
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 TLR7 35/4885ADORA2A 3459/4885LMNA 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.